Partnership to Improve Patient Care

  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Action Center
    • Value Our Health
    • International
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • News
    • Press Releases
    • PIPC in the News
    • PIPC Weekly Update
    • PIPC Patients' Blog
    • Chairman's Corner
    • The Data Mine
  • Events
    • Nevada AB 259
    • QALY Panel
    • QALY Briefing
    • Past Webinars >
      • MFN/IPI Webinar 2025
      • Discrimination & Health Care
      • C & GT Webinar
      • ICER COVID Webinar
      • Value Our Health Briefing
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Action Center
    • Value Our Health
    • International
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • News
    • Press Releases
    • PIPC in the News
    • PIPC Weekly Update
    • PIPC Patients' Blog
    • Chairman's Corner
    • The Data Mine
  • Events
    • Nevada AB 259
    • QALY Panel
    • QALY Briefing
    • Past Webinars >
      • MFN/IPI Webinar 2025
      • Discrimination & Health Care
      • C & GT Webinar
      • ICER COVID Webinar
      • Value Our Health Briefing
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010

The PIPC Blog

PIPC Patient Blog: ICER Report Adds Insult to Injury for Cystic Fibrosis Patients

5/1/2020

 
Picture
​By Siri Vaeth, MSW

My daughter, Tess, lives with cystic fibrosis (CF). She is twenty-five years old. Not too long ago that would have been unimaginable for a CF patient. I’m so grateful for the medical advances that allow my child to have a full life.

​Tess – like the majority of her peers with CF – spends hours every day following a complex medical regimen, trying to stave off lung function decline and death. In the CF community, we know too well what a capricious disease it is. One bad infection can create the “death spiral,” and we are still losing people at tragically young ages. In recent years, halting a decline in lung function was considered a win. Yet today, thanks to a new disease modifying therapy, 90% of those with CF have the potential to improve their ability to breathe. Trifkafta, a breakthrough therapy for CF, treats not just the symptoms but the underlying cause of the disease. The availability of this type of treatment means my daughter, and many patients like her, have hope and a real opportunity for the future.
​
As you can imagine, the CF community has been particularly on edge during the current COVID-19 crisis. The virus, which attacks the respiratory system, poses an extreme risk for CF patients. We have been hunkering down to care for our community. As the executive director of Cystic Fibrosis Research Inc. (CFRI), I have been focused on ensuring that CF patients are still able to access medications while sheltering in place and advocating to ensure CF patients are not subject to discrimination in favor of healthy people should they contract the disease and require hospital services and medical equipment that is in short supply. It has been a trying eight weeks.

To add insult to injury, in the middle of this crisis, the Institute for Clinical and Economic Review (ICER), a watchdog group that purports to determine whether a drug is worth its cost, released its “Evidence Report” on the ‘value’ of Trikafta. ICER’s reports are based on a discriminatory metric, the Quality-Adjusted Life Year, which quite simply measures the lives of people with disabilities and chronic illnesses, like my daughter, as less valuable than those of “healthy” people. This means ICER’s reports consistently undervalue treatments for people with diseases like CF.

ICER’s report found that Trikafta had clear clinical benefit. Indeed, they gave Trikafta an “A,” their highest rating for comparative clinical effectiveness, which, in the words of ICER staff indicates there is “high certainty that the treatment delivers substantial health benefits.” Without question, this drug is a breakthrough. For many patients it can turn CF from a definitive death sentence into a chronic life-threatening disease. Despite this clear clinical benefit, ICER also found that the drug is “not worth the cost,” even if it were a curative therapy.

Put bluntly, ICER believes that my daughter is not worth treating. Her life – and the lives of thousands of individuals suffering the impact of CF - is not worth improving. I find it horrifying that this organization is able to make decisions so divorced from humanity. Cystic fibrosis-related complications are numerous, including lung infections requiring IV intervention, hemoptysis (in which the lungs flood with blood) and pneumothorax. Many face respiratory failure, in which a risky lung transplant is the only option to potentially extend life. These are painful, and I must add, very expensive. ICER’s methodology calculated the financial costs of these heartbreaking experiences and concluded that Trikafta, which can ameliorate this expensive suffering, was simply not worth it. This conclusion is dehumanizing and beyond comprehension.

In the best of times, it is difficult for patient groups to make their voices heard in ICER’s reports. ICER claims it wants to engage the patient community, but consistently minimizes our voice, despite a tremendous investment of time on our part. In this moment, taking the time to focus on ICER means taking time away from patients when they need us most.

ICER typically has a public meeting, which is the one opportunity patients have to speak in a public forum and make clear whether they, the indicated population, find value in the treatments under question. Due to COVID, ICER postponed its CF public meeting, but still released their evidence report on Trikafta. The report should have been put on hold as well, until patients could be heard in conjunction with its release. This feels calculated, as if ICER is taking advantage of the crisis to silence those who oppose their philosophy and methodology. This includes CF patients, family members, caregivers, and advocacy groups, who at that public meeting would point out that ICER’s economic model is flawed, relying on very questionable quality of life inputs and incomplete economic measurements of CF impacts. It does not consider the non-medical costs of the disease like lost caregiver productivity and CF patients who can have full productive careers if allowed to survive to adulthood. It refuses to consider Trikafta a treatment for a rare disease when CF is considered rare under any federally accepted definition.

ICER’s reports are both flawed and insulting, but my greatest concern with them is that they serve as a tool to block access to life-saving therapies. Payers, who fund ICER, look to these reports in making their coverage decisions, as do state Medicaid programs. This is ICER’s second review of drugs for CF. After the first review, New York’s Medicaid program, relying on ICER’s results, attempted to not cover one of the drugs in question, leaving patients who had been waiting years for an effective treatment to wonder if they could access it. This is not an anomaly. We are seeing more states look to ICER for guidance, from Oklahoma to Massachusetts, which leaves me with deep concern for the future of my daughter and patients like her. In the treatment of CF, every day matters. Delays in access mean decreased lung function. We are already subject to arduous preauthorization policies that cost us valuable time, and ICER’s reports continue to encourage payers to subject us to delays, or worse, noncoverage of the treatment.

As we as a nation grapple with rising healthcare costs and the topic of value continues to surface, I encourage policymakers and payers to talk to the real experts - the patients who suffer from chronic diseases and the providers who treat them daily – to determine what works and what has value, instead of giving any credence to a self-appointed entity like ICER. 
pipc_patient_blog_siri.pdf
File Size: 88 kb
File Type: pdf
Download File


Comments are closed.

    Topics

    All
    Alternative Payment Models
    Chairman's Corner
    Patient Centered Research
    PIPC In The News
    PIPC Patient Blog
    PIPC Weekly Update
    Press Releases
    The Data Mine
    Value Frameworks

    Archives

    June 2025
    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    April 2024
    March 2024
    February 2024
    January 2024
    December 2023
    November 2023
    October 2023
    September 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    April 2013
    March 2013
    December 2012
    November 2012
    February 2012
    September 2011
    August 2011
    July 2011
    May 2011
    March 2011
    November 2010
    October 2010
    September 2010
    August 2010
    April 2010
    March 2010
    February 2010
    December 2009
    September 2009
    July 2009
    June 2009
    May 2009
    February 2009
    January 2009
    December 2008

Powered by Create your own unique website with customizable templates.